MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study
European Respiratory Journal · 2024
DOI: 10.1183/13993003.01110-2024 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Respiratory Journal, 2024. Verfasst von Marc Humbert und 8 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris-Saclay, Faculté de Médecine, Inserm UMR_S 999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (Assistance …. Hauptthemen laut MEDLINE: Soluble Guanylyl Cyclase. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: MSD Sharp and Dohme.
Abstract (Originalsprache)
Background
MK-5475 is an investigational inhaled soluble guanylate cyclase stimulator hypothesised to avoid most side-effects of systemic vasodilation.
Methods
The phase 2 INSIGNIA-PAH ( NCT04732221 ) trial randomised adults with pulmonary arterial hypertension (PAH) on stable background therapy 1:1:1:1 to once-daily dosing with placebo, MK-5475 32 µg, 100 µg or 380 µg via dry powder inhalation for 12 weeks.
Objectives
The objectives were to evaluate pulmonary vascular resistance (PVR; primary), 6-min walk distance (6MWD; secondary), additional selected haemodynamic parameters, and safety and tolerability in participants with PAH.
Results
168 participants were randomised to placebo (n=41), MK-5475 32 µg (n=42), 100 µg (n=44), and 380 µg (n=41). Median age was 51 years. Most participants were female (73.8%), diagnosed with idiopathic PAH (63.7%), receiving concomitant phosphodiesterase type 5 inhibitors (PDE5i; 93.5%), and treated with double or triple combination therapy (85.1%). At week 12, the placebo-corrected changes in PVR by least-squares means were −9.2% (95% CI −21.3%, 2.9%; p=0.068) with 32 µg, −22.0% (95% CI −33.7%, −10.3%; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Université Paris-Saclay, Faculté de Médecine, Inserm UMR_S 999, Service de Pneumologie et Soins Intensifs Respiratoires, Hôpital Bicêtre (Assistance Publique - Hôpitaux de Paris), Le Kremlin-Bicêtre, France marc.humbert…
- Johns Hopkins University School of Medicine, Baltimore, MD, USA.
- University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Sanatorio de la Trinidad Mitre, Buenos Aires, Argentina.
- Merck & Co., Inc., Rahway, NJ, USA.
- Hannover Medical School, Hannover, Germany.
ORCID-Profile: Marc Humbert, Paul M Hassoun, Kelly M Chin, Guillermo Bortman, Maria José Loureiro, Marius M Hoeper
Förderung
- MSD Sharp and Dohme
Zitieren
APA
Humbert, M., Hassoun, P. M., Chin, K. M., Bortman, G., Patel, M. J., La Rosa, C., Fu, W., Loureiro, M. J., & Hoeper, M. M. (2024). MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. European Respiratory Journal. https://doi.org/10.1183/13993003.01110-2024
Vancouver
Humbert M, Hassoun PM, Chin KM, Bortman G, Patel MJ, La Rosa C, et al. MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study. European Respiratory Journal. 2024. doi:10.1183/13993003.01110-2024
BibTeX
@article{Humbert2024,
author = {Humbert, Marc and Hassoun, Paul M and Chin, Kelly M and Bortman, Guillermo and Patel, Mahesh J and La Rosa, Carmen and Fu, Wei and Loureiro, Maria José and Hoeper, Marius M},
title = {MK-5475, an inhaled soluble guanylate cyclase stimulator, for treatment of pulmonary arterial hypertension: the INSIGNIA-PAH study},
journal = {European Respiratory Journal},
year = {2024},
doi = {10.1183/13993003.01110-2024}
}
EUVIMED